Ariceum Therapeutics expands Series A financing to EUR 47.75 million.

Munich, Germany — Ariceum Thera­peu­tics (Ariceum) successfully closes a Series A expan­sion finan­cing, raising an addi­tio­nal EUR 22.75 million for Ariceum on top of the EUR 25 million Series A finan­cing announ­ced in June 2022.

With this, Ariceum, a priva­tely held biotech­no­logy company based in Berlin, Germany, aims to advance its clini­cal pipe­line of next-gene­ra­­tion radio­phar­maceu­ti­cals and further expand the company, with a focus on its proprie­tary peptide deri­va­tive sato­reo­tide, as well as a pipe­line of other projects. New inves­tors Andera Part­ners and Early­bird Venture Capi­tal join exis­ting inves­tor Pureos Bioven­tures in expan­sion financing.

Olivier Litzka from Andera Part­ners and Chris­toph Mass­ner from Early­bird Venture Capi­tal become addi­tio­nal members of Ariceum’s advi­sory board.

Baker McKen­zie advi­sed Ariceum Thera­peu­tics on all legal aspects rela­ted to the finan­cing. “Toge­ther with our client and our team of specia­li­zed corporate/M&A and life scien­ces lawy­ers, we have succee­ded in secu­ring further finan­cing for Ariceum, paving the way for the deve­lo­p­ment of thera­pies for pati­ents suffe­ring from certain diffi­­cult-to-treat cancers,” commen­ted Julia Braun, LL.M., the lead part­ner on the transaction.

Legal advi­sor Ariceum Thera­peu­tics: Baker McKenzie

Lead: Julia Braun (Corporate/M&A, Part­ner, Munich)
Erik Kuhn (Asso­ciate, Munich), Anna Dzik (Asso­ciate, Munich)

About Baker McKenzie

Complex busi­ness chal­lenges require a holi­stic response across diffe­rent markets, sectors and juris­dic­tions. Baker McKenzie’s solu­ti­ons for clients are accom­pa­nied by seam­less advice, under­pin­ned by in-depth prac­tice and indus­try know­ledge as well as excel­lent local market insights. In more than 70 offices world­wide, we work with our clients to provide solu­ti­ons for a connec­ted world.